The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 1013-1023

  Blum, Robert A ^a   Shi, Harry ^b   Karol, Michael D ^b   Greski Rose, Pam A ^c   Hunt, Richard H ^d  

^a MILLARD FILLMORE HOSPITAL   (United States)

^b ABBOTT LABORATORIES   (United States)

^c TAP Holdings Inc   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Intragastric pH; Lansoprazole; Omeprazole; Ranitidine

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; RANITIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; STOMACH ULCER;

EID: 0030665639     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80053-7     Document Type: Article

References (17)

1. Decktor DL, Robinson MG. Gastroesophageal reflux: Clinical diagnosis, current therapy, future trends. Hepatogastroenterology. 1990;37(Suppl 1): 11-17.
2. Weinbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol. 1989;24(Suppl 156):7-13.
3. Bell NJV, Burget D, Howden WC, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59-67.
4. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology. 1997;112:1798-1810.
5. Orlando RC. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Am J Gastroenterol. 1996; 91:1692-1696.
6. Dodds WJ, Hogan WJ, Helm JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology. 1981;81:376-394.
7. Gillen P, Keeling P, Byrne PJ, Hennessy TPJ. Barren's oesophagus: pH profile. Br J Surg. 1987;74:774-776.
8. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut. 1987;28: 1484-1488.
9. Fiorucci S, Santucci L, Morelli A. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis. Am J Gastroenterol. 1990;85: 1458-1462.
10. Ducrotte P, Guillemot F, Elouaer-Blanc L, et al. Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: A cross-over study. Am J Gastroenterol. 1994;89(5):717-721.
11. Dammann HG, Fuchs W, Richter G, et al. Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther. 1997; 11: 359-364.
12. Tolman KG, Sanders SW, Buchi N, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol. 1997;24:65-70.
13. Bruley des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther. 1994;8(3):309-314.
14. Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol. 1995;20(Suppl 1):S7-S9.
15. Atanassoff PG, Brull SJ, Weiss BM, et al. The time course of gastric pH changes induced by omeprazole and ranitidine: A 24-hour dose-response study. Anesth Analg. 1995;80(5):975-979.
16. Houben GM, Hooi J, Hameeteman W, Stockbrugger RW. Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. Aliment Pharmacol Ther. 1995;9(6):649-654.
17. Howden CW, Meredith PA, Forrest JAH, Reid JL. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol. 1984; 26:641-643.